Semaglutide
Also known as: Semaglutide (GLP-1 agonist)
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the incretin hormone GLP-1 to regulate appetite and glucose metabolism.
Pricing for Semaglutide
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
Average price
$9.28/mg
range $1.00–$44.70/mg
Sellers
62
from $0.00
45-day trend
+23.4%
vs 45-day avg $/mg
54 of 62 sellers have a current price· 42 stale listings hidden (not seen in 7 days)
Top Merit pick
🇺🇸 Peptide Partners99via Disclosed Labs · 4h ago
$4.88/mg -47.4% vs avg$976
200mg
99.9% purity 14 COAs- 🇺🇸 Profound Aminos95
via Disclosed Labs · 4h ago
$7.65/mg -17.5% vs avg$153
20mg
- 🇺🇸 Prime Peptides95
via Disclosed Labs · 4h ago
$8.67/mg -6.6% vs avg$130
15mg
- 🇨🇳 Reta Peptide83
✓ verified at source · 4d ago · stale
$6.50/mg -29.9% vs avg$65.00
10mg
99.6% purity 7 COAs - 🇺🇸 Blank Peptides81
✓ verified at source · 4h ago
$10.50/mg +13.2% vs avg$105
10mg
99.8% purity 2 COAs - 🇺🇸 OROS Research79
via Disclosed Labs · 4h ago
$9.00/mg -3% vs avg$89.99
10mg
99.0% purity 1 COA - 🇺🇸 Texpeptide70
✓ verified at source · 3h ago
$7.50/mg -19.1% vs avg$150
20mg
no purity - 🇭🇰 Hkuppeptide50
✓ verified at source · 4h ago
$1.00/mg -89.2% vs avg$10.00
10mg
no purity - 🇭🇰 zztai Peptide Ltd43
✓ verified at source · 4d ago · stale
$3.87/mg -58.3% vs avg$116
30mg
no purity - 🇺🇸 Polaris PeptidesUnscored
✓ verified at source · 4h ago
$9.00/mg -3% vs avg$90.00
10mg
no purity - optimasupply.isUnscored
via Disclosed Labs · 4h ago
$11.00/mg +18.6% vs avg$110
10mg
no purity - 🇺🇸 Bulk PeptidesUnscored
✓ verified at source · 4h ago
$18.00/mg +94.1% vs avg$180
10mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
COAs for Semaglutide
153 third-party tests across 20 vendors. Each card links to the full report.
For
Semaglutide
by Peptide Partners· batch SPL-4149
For
Semaglutide
by Peptide Plugs· batch 125-01-SM
For
Semaglutide
by EZ Peptides· batch EZP-1P1005102026-03
For
Semaglutide
by EZ Peptides· batch EZP-1P1005102026-03
For
Semaglutide
by Pepsgpt· batch P-2885342-P
For
Semaglutide
by Prime Peptides· batch 3022026SM
For
Semaglutide
by Prime Peptides· batch 3142026SM
For
Semaglutide
by Prime Peptides· batch 2242026SM
For
ION-1S
by Ion Peptide· batch ION1S20-04172026
For
Semaglutide
by OROS Research· batch OR-LPGLPS10-426-B3
For
Semaglutide
by Prime Peptides· batch 3272026SM
For
Semaglutide
by Prime Peptides· batch 3222026SX
For
Semaglutide
by Blank Peptides· batch 665394
For
Semaglutide
by Prime Peptides· batch 2182026SM
For
Semaglutide
by Prime Peptides· batch 2122026SM
For
Semaglutide
by Orbitrex Peptides· batch 1G200426
For
Semaglutide
by Qihang Peptide· batch 3
For
Semaglutide
by Reta One Labs· batch SM100326
For
Semaglutide
by Reta One Labs· batch SM200326
For
Semaglutide
by EZ Peptides· batch EZP-1P0502152026-01
For
Semaglutide
by EZ Peptides· batch EZP-1P0502152026-01
For
Semaglutide
by Reta One Labs· batch SM100326
For
Semaglutide
by Reta One Labs· batch SM200326
For
Semaglutide
by Prime Peptides· batch 1052026SM
23 citations indexed for Semaglutide
Study · 2026
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial
Background This phase 2 study evaluated once-weekly zalfermin and semaglutide for efficacy and safety in patients with metabolic dysfunction-associated steatohepatitis and clinically significant fibrosis, including patients with compensated cirrhosis (F4c).
animal · 2026
Semaglutide and Exercise Synergy in Obesity: Preserving Muscle Mass and Uncovering Organ Crosstalk
Background Semaglutide, a glucagon-like peptide-1 receptor agonist, effectively promotes weight loss and improves metabolic parameters in individuals with obesity. However, its use is often accompanied by reductions in lean mass, raising concerns about long-term muscle health.
cohort · 2026
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials
Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.
Study · 2026
Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists
Aims Neuropsychiatric safety concerns, including depression and suicidal ideation, have emerged during the expanding clinical use of incretin-based therapies for type 2 diabetes mellitus (T2DM) and obesity. However, whether risks differ across successive generations of incretin-based therapies remains uncertain.
Study · 2026
Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes
This retrospective cohort study evaluated whether semaglutide and tirzepatide reduce the risk of falls and femoral fractures in older adults with type 2 diabetes and overweight or obesity. The findings showed significantly lower risks of both outcomes compared with DPP-4 inhibitors.
Study · 2026
Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes
Aim In December 2022, semaglutide injections for weight management were marketed in Denmark. Pre-marketing trials documented high efficacy when adherence to the treatment and the recommended dose titration schedule was followed.